Omnia Education: Recent Episodes
ReachMD
Omnia Education is exclusively focused on women’s health and the ways in which diseases and conditions impact the female patient. That unique focus on the female patient has allowed Omnia Education to transform the CME learning environment for healthcare professionals nationwide. Our leading position in women's health education is evidence of our ability to help learners recognize and overcome barriers to optimal performance and optimal patient outcomes. Ultimately, our education improves clinician knowledge, awareness, attitudes, competencies, and performance in practice.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Linda Bradley, MD
Guest: Melissa Simon, MD
Both provider- and patient-related healthcare disparities exist in the diagnosis and management of endometriosis. Many disparities derive from incorrect historical biases, while others are associated with social determinants of health, or SDOH. Join Drs. Lee Shulman, Linda Bradley, and Melissa Simon as they address these issues to help facilitate a patient-centered practice environment for all patients.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP
Guest: James A. Simon, MD, CCD, NCMP, IF, FACOG
While both medical therapy and surgery often play a role in a woman’s journey with endometriosis, it is less clear how to best sequence these approaches to optimize a patient’s outcomes. Under what circumstances should you consider using a GnRH antagonist either before or after conservative surgery? Join Drs. Lee Shulman, Ayman Al-Hendy, and James Simon as they provide their collective thoughts on how best to sequence a GnRH antagonist with conservative surgery when managing endometriosis.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP
Guest: Sawsan As-Sanie, MD
GnRH antagonists have emerged as a viable first-line (or subsequent-line) medical therapy for the management of endometriosis. They have proven to be effective and safe, and their use avoids the flare response observed with GnRH agonists. Join Drs. Lee Shulman, Ayman Al-Hendy, and Sawsan As-Sanie as they discuss the estrogen threshold hypothesis from the perspective of GnRH antagonists and delve into clinical data supporting the use of GnRH antagonists in the medical management of endometriosis.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Linda Bradley, MD
Guest: Melissa Simon, MD
The use of validated patient questionnaires, notably the SF-36 and EHP-30 scales, can greatly hasten the suspicion for an endometriosis diagnosis. Coupled with shared decision-making, or SDM, this patient-centered process can help ensure therapeutic adherence. Join Drs. Lee Shulman, Melissa Simon, and Linda Bradley as they discuss how to utilize the SF-36 and EHP-30 questionnaires in clinical practice and explore strategies to facilitate patient-healthcare provider discussions to improve overall short- and long-term patient outcomes.
Host: Kara B. Markham, MD
Guest: Kenneth J. Moise Jr., MD
Hemolytic disease of the fetus and newborn (HDFN) is an alloimmune disorder between the mother and fetus, one with significant risk for dire health consequences for both. Fortunately, a better understanding of the neonatal Fc receptor (FcRn) pathway along with the emergence of an inhibitor of this pathway has brought with it an opportunity to greatly reduce the potential harm associated with HDFN. Join us as Drs. Kenneth Moise and Kara Markham discuss the pathophysiology of HDFN and present key clinical data that may change the landscape of medical intervention for HDFN.
Host: Warner K. Huh, MD
Guest: Kimberly Levinson, MD, MPH
More effective triage tests are essential to improving cervical cancer risk-stratification and thus reducing the potential for unnecessary colposcopies. Enduring consensus cervical cancer screening recommendations, published in 2024, describe specific-use algorithms for p16/Ki-67 dual-staining cytology as an effective triage test, and also offer insight on how this test can best fit into clinical practice. Join Drs. Warner Huh and Kimberly Levinson as they first establish the rationale for using p16/Ki-67 dual-staining cytology and then break down the most salient algorithms for its use as offered in the recent recommendations.
Host: Jessica Ailani, MD
Guest: Dawn C. Buse, PhD
Half of the women in the US with migraine are never diagnosed. Of those who are, the journey to effective treatment may last a decade or longer. But newer and more effective targeted treatments are beginning to make a difference. Join Drs. Jessica Ailani and Dawn Buse as they discuss a novel approach to managing migraine and interview a patient whose migraine journey is unfortunately one traversed by many women.
Host: Anita L. Nelson, MD
Guest: Barbara Dehn, Np, FAANP, NCMP
Understanding the physiologic basis for the vasomotor symptoms of perimenopause/menopause has led to an improved ability to match a therapeutic approach to each individual patient. New and improved agents are helping to facilitate this dynamic. Join Anita Nelson, MD, and Barbara Dehn, NP, as they provide insights into making the right treatment decision for each patient—one that includes ensuring patient preferences are considered.
Host: Lee Shulman MD, FACOG, FACMG
Guest: Kristina Deligiannidis, MD
The recent development and approval of two neuroactive steroids is likely to change the treatment paradigm for moderate to severe postpartum depression (PPD). These agents have a quick onset and function as GABAA positive allosteric modulators. Join Drs. Shulman and Deligiannidis as they address the burdens and impacts of PPD on mothers, babies, and partners, and deep dive into the pathophysiologic role and clinical findings associated with the use of neuroactive steroids in the management of PPD.
Host: Jessica Ailani, MD
Guest: Dawn C. Buse, PhD
Upwards of 47 million people in the U.S. suffer from migraines, often accompanied by widespread personal, professional, and social disabilities. Though a similar prevalence is initially observed between men and women, by mid-adulthood the prevalence of migraine is 3-fold greater in women than men. Newer agents, both injectable and oral and focused on modulating the calcitonin gene-related peptide pathway, have emerged and have proven highly effective in managing both acute and chronic migraine. Join Drs. Jessica Ailani and Dawn Buse as they provide an overview of the changing landscape of migraine therapy, especially as it impacts women across different life-stages.
Host: Warner K. Huh, MD
Guest: Sarah E. Dilley, MD, MPH, FACOG
Effective triage tests are needed to lessen diagnostic uncertainty when assessing cervical cancer risk and selecting which patients will move on to colposcopy. An FDA-approved dual-staining cytology test is available that can help in decision-making for a wide range of patients. Join Drs. Warner Huh and Sarah Dilley as they address current 2019 ASCCP guidelines and anticipate potential updates to ASCCP’s guidance in 2023.
Host: Arjeme Denise Cavens, MD
Guest: Lee Shulman MD, FACOG, FACMG
This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.
Host: Malcolm G. Munro MD, FRCS(c), FACOG
Guest: Wendy Wright, DNP, FNP-BC, ANP-BC, FAANP, FAAN, FNAP
This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.
Host: Malcolm G. Munro MD, FRCS(c), FACOG
Guest: Arjeme Denise Cavens, MD
This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.
Host: Malcolm G. Munro MD, FRCS(c), FACOG
Guest: Michael K. Georgieff, MD
This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.
Host: Malcolm G. Munro MD, FRCS(c), FACOG
Guest: Michael Auerbach, MD
This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.
Host: Malcolm G. Munro MD, FRCS(c), FACOG
Guest: Arjeme Denise Cavens, MD
This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.
Host: Malcolm G. Munro MD, FRCS(c), FACOG
Guest: Wendy Wright, DNP, FNP-BC, ANP-BC, FAANP, FAAN, FNAP
This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.
Host: Malcolm G. Munro MD, FRCS(c), FACOG
Guest: Michael Auerbach, MD
This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.
Host: Malcolm G. Munro MD, FRCS(c), FACOG
Guest: Michael Auerbach, MD
This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.
Host: Malcolm G. Munro MD, FRCS(c), FACOG
Guest: Michael Auerbach, MD
This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.
Host: Malcolm G. Munro MD, FRCS(c), FACOG
Guest: Arjeme Denise Cavens, MD
This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.
Host: Warner K. Huh, MD
Guest: Leigh Anne Cantrell, MD, MSPH
Explore the case of a young patient to see the ACS and ASCCP cervical cancer screening guidelines in action. Who needs to be screened, how is it best to screen, and what's the best test? Leading experts, Drs. Leigh Cantrell and Warner Huh, review the benefits of primary screening as they explore shifts in current guidelines. Find out how you can improve outcomes for patients, not only through appropriate primary HPV testing in lieu of cytology as the screening modality, but also by reinforcing how a “negative” HPV test actually sends a powerful “positive” message. As a bonus, you might just change a young patient’s life.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Alexandra Benachi, MD, PhD
Guest: Julien Zuber, MD, PhD
Program Chairman:
Roberto Romero, MD, DMedSci
Chief, Perinatology Research Branch
Division of Maternal-Fetal Medicine and Obstetrics
Division of Intramural Research
NICHD/NIH/DHHS
Editor-in-Chief for Obstetrics
The American Journal of Obstetrics and Gynecology
There exists a long-standing controversy about drawing parallels between transplant and pregnancy immunology. Listen in as Drs. Alexandra Benachi, Julien Zuber, and Lee Shulman discuss why these considerations are so important for you and your colleagues, patients, and their families to understand. Discover how links between kidney transplantation and maternal anti-fetal rejection may impact your practice and spark new pathways in medicine.
Host: Warner K. Huh, MD
Guest: Leigh Anne Cantrell, MD, MSPH
Guest: Mark H. Stoler, MD
Experts discuss the ACS and ASCCP CCV screening guidelines and review the benefits of primary screening and the latest data driven testing options. Is Pap cytology a thing of the past? Find out more about harmonization of guidelines from leading experts, Drs. Cantrell, Stoler and Huh. You might just transform your clinical practice.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Masja de Haas, MD, PhD
Program Chairman:
Roberto Romero, MD, DMedSci
Chief, Perinatology Research Branch
Division of Maternal-Fetal Medicine and Obstetrics
Division of Intramural Research
NICHD/NIH/DHHS
Editor-in-Chief for Obstetrics
The American Journal of Obstetrics and Gynecology
Neonatal alloimmune neutropenia (NAIN or NIN) is a neutrophil blood group antagonism similar to HDFN and FNAIT. Its presentation varies clinically and ranges from asymptomatic to severe manifestations such as sepsis and meningitis. Listen in as Drs. Masja de Haas and Lee Shulman discuss clinical clues that should catch your eye. Discover novel yet simple ways to be vigilant and make the right clinical calls.
Host: Andrea Singer, MD, FACP, CCD
Guest: Susan V. Bukata, MD, FAOA, FAAOS
Life-altering secondary fractures are a harsh reality, but Medicare studies show, and orthopedic surgeons agree, that knowledge has not translated into prevention. Why is there clinical inertia in providing preventative interventions related to secondary fragility fractures? Join Drs. Andrea Singer and Susan Bukata as they provide a cogent medical approach to preventing these fractures and a roadmap for when and how to use available therapies based on their mechanisms of action.
Host: Lee Shulman MD, FACOG, FACMG
Guest: Andrea S. Lukes, MD, MHSc, FACOG
Are you currently considering GnRH antagonists as first-line therapy, or are you waiting for patients to fail other endometriosis treatment approaches first? Drs. Andrea Lukes and Lee Shulman discuss how the advent of effective GnRH antagonists is evolving the care of endometriosis. Are you ready to provide patients with the clinical outcomes they seek while balancing the benefits of medical and surgical approaches?
Host: Michael Krychman, MD
For affected women, acute vulvovaginal candidiasis (VVC) brings with it a significant health burden, and the substantial morbidity and poor quality of life associated with recurrent disease (RVVC) requires improved diagnosis, management, and quality of care. Join Dr. Michael Krychman as he dissects the barriers to managing VVC and RVVC and provides insights on diagnosis and management based on guidelines, plus an overview of innovative therapeutic agents. The unique qualities of the current and emerging therapeutic interventions may well represent a significant step forward in how you manage these challenging infections.
Host: Anita H. Clayton, MD
Guest: Jennifer L. Payne, MD
This animated Women’s Health 2022 lecture features a discussion between Drs. Jennifer Payne and Anita Clayton who clearly highlight the importance of screening for perinatal and postpartum depression (PPD). Our experts delve into the critical importance of proactively diagnosing and treating women during the various stages of pregnancy and review the latest therapies that specifically target PPD. Find out how these therapies compare to traditional antidepressants and how PPD treatment can improve the health and quality of life for patients and their families. What changes can you implement into your clinical practice to improve maternal and infant health?
Host: Hugh S. Taylor, MD
Endometriosis is challenging to diagnose, with approximately 6 to 11 years from symptom onset to definitive diagnosis and treatment. Many medical providers are not adequately familiar with the disease, and this, coupled with historically limited medical options, has resulted in surgical approaches often being considered as the first treatment option. Join us as Dr. Hugh Taylor discusses how this landscape is changing to one in which safe and effective medical options can now offer improved outcomes for our patients with endometriosis.
Host: Jennifer L. Payne, MD
Optimizing the management of comorbid depression and menopause is a significant clinical challenge. When the darkness begins to set in, are you able to hear your patients’ needs and deliver life-changing treatment?
Join Dr. Jennifer Payne as she provides concrete tips and explores the latest guidelines and research on therapies that improve vasomotor symptoms, mood, and perimenopausal depression. Get ready to offer new hope to your patients as you help them cool off and begin to see the dawn of a new day.
Host: David L. Eisenberg, MD, MPH, FACOG
Intrauterine devices and contraceptive implants, also called long-acting reversible contraceptives (LARCs), are the most effective reversible contraceptive methods. The major advantage of LARCs compared with other reversible contraceptive methods is that they do not require ongoing effort on the part of the patient for long-term, effective use. In addition, after the device is removed, the return of fertility is rapid. Join Dr. David Eisenberg has he discusses when LARCs should be recommended as a first-line contraceptive choice and when they should not. He further details how to approach a shared decision-making discussion with patients about their contraceptive options.
Host: Andrew M. Kaunitz, MD, FACOG
By the age of 50, ultrasound imaging demonstrates that 70%-80% of women have fibroids. Uterine fibroids are associated with disability similar to other chronic diseases. They can even lead to lower vitality and social function than are experienced by women with breast cancer. Fibroid-related hysterectomies account for 45% of all US hysterectomies, but a surgical approach is no longer one size fits many. Join Dr. Andrew Kaunitz as he describes the clinical presentations of fibroids and how newly emergent medical options greatly improve fibroid-related symptoms, provide time to consider other alternatives, and can be used to bridge the transition to menopause.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: James B. Bussel, MD
Program Chairman:
As the platelet equivalent of hemolytic disease of the fetus and newborn, fetal and neonatal alloimmune thrombocytopenia (FNAIT) is an uncommon yet complex and life-threatening bleeding disorder that results from incompatibility between mother and baby for platelet-specific antigens. Despite relatively normal platelet function, in the setting of severe thrombocytopenia, intracranial hemorrhage is a consequence. Drs. Shulman and Bussel discuss advances in management strategies and concrete steps you can take to lower the risk and stop the progression of this disorder in your patients.
Host: Lee Shulman MD, FACOG, FACMG
Guest: Ayman Al-Hendy, MD
GnRH antagonists are revolutionizing the medical management of uterine fibroids. Drs. Al-Hendy and Shulman discuss how medical myomectomy with GnRH antagonists is revolutionizing care by bridging gaps during 3 different stages of patients’ lives.
Host: Lee Shulman MD, FACOG, FACMG
Guest: Elizabeth Stewart, MD
Fertility preservation is a significant clinical concern for all women of reproductive age diagnosed with endometriosis or uterine fibroids (UF). Drs. Elizabeth Stewart and Lee Shulman discuss how the advent of GnRH antagonists is affecting how we approach these 2 conditions. Management trends are evolving beyond reflexive, prophylactic surgery, so are you ready to change with the times?
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Kenneth J. Moise Jr., MD
Program Chairman:
How well do you understand the biology of hemolytic disease of the fetus and newborn (HDFN)? What about its connection to the FcRn receptor pathway and IgG? Drs. Lee Shulman and Ken Moise go beyond the basics taught in medical school immunology and look more closely at FcRn’s role in protecting IgG. With an improved understanding of these mechanisms, we can expand therapeutic targets beyond the fetus and newborn and finally put the needles away.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Linda Bradley, MD
Join Drs. Linda Bradley and Lee Shulman as they discuss factors contributing to disparities in care for patients with endometriosis and/or uterine fibroids. They offer practical tips to overcome the disproportionate disease burden that especially impacts women of color. Cut through the noise to clearly hear each patient’s voice. Your clinical impact may be profound.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Kenneth J. Moise Jr., MD
Program Chairman:
Are you taking the right steps to consistently ensure all of your patients at risk of alloimmune disorders of pregnancy, specifically HDFN, receive a helping hand plus timely and appropriate clinical care? Despite having considerable clinical consequences, this area of medicine is not fully understood by many clinicians. Drs. Shulman and Moise provide expert insight on red blood cell alloimmunization, highlighting essential pathophysiology and current and evolving management strategies. Join us to learn new ways to approach this complicated and rare clinical condition.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Nanette F. Santoro, MD
Tune out the noise and get to the heart of managing menopause and associated vasomotor symptoms. This program provides highlights from the 2022 American College of Obstetricians and Gynecologists Annual Clinical and Scientific Meeting. Join Drs. Nanette Santoro and Lee Shulman as they dive into the latest research, which could alter your current practice patterns and help your patients cool off.
Host: Ayman Al-Hendy, MD
Despite its profound impact, endometriosis remains critically undermanaged. This program provides highlights from a live symposium at the annual meeting for obstetrics and gynecology professionals and is based on patient & provider surveys. Join Dr. Ayman Al-Hendy to explore management gaps, the role of GnRH antagonists in addressing deficits, and the latest research, which he presented with Drs. Andrea Lukes and Lee Shulman—you might just alter your current practice patterns.
Host: Jeffery D. Dunn, PharmD, MBA
Guest: Gary M. Owens, MD
Guest: Anita L. Nelson, MD
Are you ready to see what is on the horizon to more effectively navigate vasomotor symptoms (VMS)? Join Drs. Dunn, Owens, and Nelson as they discuss highlights from a symposium held at AMCP 2022 featuring the latest data on the impact of menopause and evolving treatments options. They provide guidance, context, and recommendations for the medical management of VMS beyond estrogen. The nonhormonal treatment options that are currently being studied represent a new horizon for both patients and payers.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Stephanie Martin, DO
How ready are you to go beyond simply ordering CBCs and recognizing anemia? Join Drs. Martin and Shulman as they discuss the latest developments in oral and IV iron therapies. Learn how you may take a more active role in managing iron deficiency anemia, focusing on abnormal uterine bleeding.
Participating in this activity will ensure that you are prepared to address the goals with your patients by improving access and adherence to efficacious and convenient therapies.
Host: Patty Cason, RN, MS, FNP-BC
Guest: Joely Pritzker, RN, MS, FNP-C
Are you ready to apply the latest counseling techniques to address the contraceptive revolution?
Join nurse practitioners Patty Cason and Joely Pritzker as they briefly review the history of contraceptive counseling and then use case vignettes to illustrate how shared decision-making techniques will support the appropriate use of nonhormonal contraceptive options, such as the vaginal pH modulator (VPM).
Participating in this activity will ensure that you are ready to effectively counsel patients on their many options so that each patient’s reproductive and sexual health goals can be met.
Host: David J. Portman, MD
Guest: Patty Cason, RN, MS, FNP-BC
Guest: David L. Eisenberg, MD, MPH, FACOG
Are you ready for the contraceptive revolution? Are you applying the latest information on contraceptive efficacy, recent clinical trial data, and sexual satisfaction when counseling your patients on contraceptive options? Join Dr. David Portman, Dr. David Eisenberg, and Ms. Patty Cason as they discuss the novel mechanisms of action of cutting-edge, non-hormonal contraceptive options, such as the vaginal pH modulator (VPM). Participating in this activity will ensure that you are prepared to discuss sexual and reproductive goals with your patients and confirm that your patients’ goals are being met.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Ayman Al-Hendy, MD
Surgery has long been the default choice when managing uterine fibroids and endometriosis. However, over the past few years, reliable and durable medical interventions have emerged, notably GnRH antagonist therapy. Clinical trial data for GnRH antagonists highlight both their safety and efficacy for a broad demographic of patients. Join Drs. Lee Shulman and Ayman Al-Hendy as they discuss the “how” and the “why” of a paradigm shift that is occurring, changing our focus from surgery to first-line medical intervention for uterine fibroids and endometriosis.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Ayman Al-Hendy, MD
Surgery has long been the default choice when managing uterine fibroids and endometriosis. However, over the past few years, reliable and durable medical interventions have emerged, notably GnRH antagonist therapy. Clinical trial data for GnRH antagonists highlight both their safety and efficacy for a broad demographic of patients. Join Drs. Lee Shulman and Ayman Al-Hendy as they discuss the “how” and the “why” of a paradigm shift that is occurring, changing our focus from surgery to first-line medical intervention for uterine fibroids and endometriosis.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Andrea S. Lukes, MD, MHSc, FACOG
By 50 years of age, 70% to 80% of women are affected by uterine fibroids, and nearly 10% of women are affected by endometriosis. Clinical trial data demonstrate that GnRH antagonist therapy can dramatically impact pain and bleeding and improve results across all EHP-30 domains. Join Drs. Lee Shulman and Andrea Lukes as they dive into these data and offer strategies to help you better incorporate patient-centric medical management for uterine fibroids and endometriosis into your clinical practice.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Andrea S. Lukes, MD, MHSc, FACOG
By 50 years of age, 70% to 80% of women are affected by uterine fibroids, and nearly 10% of women are affected by endometriosis. Clinical trial data demonstrate that GnRH antagonist therapy can dramatically impact pain and bleeding and improve results across all EHP-30 domains. Join Drs. Lee Shulman and Andrea Lukes as they dive into these data and offer strategies to help you better incorporate patient-centric medical management for uterine fibroids and endometriosis into your clinical practice.
Guest: Peter Goadsby, MD, PhD, DSc
Guest: Kathleen B. Mullin, MD
Women with migraine have unique needs that often remain undermanaged. Have you taken a critical look at the standard of care and how current treatment strategies have recently shifted? Groundbreaking research on the calcitonin gene-related peptide (CGRP) pathway has led to the development of new medications that act on the specific cascade of inflammatory response associated with migraine. Also called gepants, the CGRP receptor antagonists confer clinical benefit to patients who seek better control of their migraines.
Tune in to this Women’s Health 2021 program to hear our experts, Drs. Peter Goadsby and Kathleen Mullin, discuss the diagnosis of migraine with a focus on the recent evolution of acute and preventive treatment strategies and the role of gepants. Are you doing all you can to ensure that your patients’ needs are optimally addressed?
Guest: Peter Goadsby, MD, PhD, DSc
Guest: Kathleen B. Mullin, MD
Women with migraine have unique needs that often remain undermanaged. Have you taken a critical look at the standard of care and how current treatment strategies have recently shifted? Groundbreaking research on the calcitonin gene-related peptide (CGRP) pathway has led to the development of new medications that act on the specific cascade of inflammatory response associated with migraine. Also called gepants, the CGRP receptor antagonists confer clinical benefit to patients who seek better control of their migraines.
Tune in to this Women’s Health 2021 program to hear our experts, Drs. Peter Goadsby and Kathleen Mullin, discuss the diagnosis of migraine with a focus on the recent evolution of acute and preventive treatment strategies and the role of gepants. Are you doing all you can to ensure that your patients’ needs are optimally addressed?
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Erica E. Marsh MD, MSCI, FACOG
Hear from Dr. Erica Marsh and Dr. Lee Shulman as they discuss the burden, prevalence, and treatment of uterine fibroids and endometriosis and the disproportionate impact these conditions have on vulnerable populations. Learn how to prioritize early diagnosis and treatment to improve outcomes for your patients; as well as evaluating barriers to proper diagnosis and treatment
Our experts offer strategies to guide discussions beyond surgical treatment approaches to include pharmacotherapeutic options such as GnRH agonists and new oral GnRH antagonists. Open communication with patients allows them to carefully consider symptom severity, risks, and fertility preferences to optimize treatment outcomes and patient satisfaction. Tune in to make sure that you’re really doing all you can for your patients.
Host: Anita L. Nelson, MD
How confident are you in determining which of your patients with endometriosis are suitable candidates for medical intervention? Do you ask about each patient’s goals and preferences? Have you heard about the paradigm shift occurring in the medical management of endometriosis?
While medical management of endometriosis is often a secondary consideration to surgery, it should often be the first line of treatment. Join Dr. Anita Nelson as she discusses long-standing and novel medical strategies for managing endometriosis. Find out how you can use shared decision-making strategies to help you provide more options to your patients. Join us and take an important first step that can improve outcomes and quality of life for your patients while enabling them to make educated decisions about their immediate and long-term treatment.
Host: Anita L. Nelson, MD
In this Women’s Health 2021 lecture, Dr. Anita Nelson discusses why uterine fibroids are such a high priority for both women and their clinicians. Listen in as she shares strategies to engage patients in discussions about their fibroid symptoms and their preferences for treatment. Dr. Nelson also evaluates the latest evidence on the mechanisms of action, safety, and efficacy of the newer class of therapies that are now available and can improve the quality of life for women with fibroids.
Host: Anita H. Clayton, MD
Listen in as Dr. Anita Clayton takes us through the importance of screening for postpartum depression (PPD) and reaching an early diagnosis in the perinatal and postnatal stages of pregnancy. This Women’s Health 2021 lecture also covers the exciting new agents that are targeted specifically for PPD. Find out how they compare to the traditional antidepressants and how they can improve the quality of life for your patients with PPD.
Host: Anita L. Nelson, MD
In this Women’s Health 2021 lecture, Dr. Anita Nelson discusses why uterine fibroids are such a high priority for both women and their clinicians. Listen in as she shares strategies to engage patients in discussions about their fibroid symptoms and their preferences for treatment. Dr. Nelson also evaluates the latest evidence on the mechanisms of action, safety, and efficacy of the newer class of therapies that are now available and can improve the quality of life for women with fibroids.
Host: Anita L. Nelson, MD
How confident are you in determining which of your patients with endometriosis are suitable candidates for medical intervention? Do you ask about each patient’s goals and preferences? Have you heard about the paradigm shift occurring in the medical management of endometriosis?
While medical management of endometriosis is often a secondary consideration to surgery, it should often be the first line of treatment. Join Dr. Anita Nelson as she discusses long-standing and novel medical strategies for managing endometriosis. Find out how you can use shared decision-making strategies to help you provide more options to your patients. Join us and take an important first step that can improve outcomes and quality of life for your patients while enabling them to make educated decisions about their immediate and long-term treatment.
Host: Anita H. Clayton, MD
Listen in as Dr. Anita Clayton takes us through the importance of screening for postpartum depression (PPD) and reaching an early diagnosis in the perinatal and postnatal stages of pregnancy. This Women’s Health 2021 lecture also covers the exciting new agents that are targeted specifically for PPD. Find out how they compare to the traditional antidepressants and how they can improve the quality of life for your patients with PPD.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Erica E. Marsh MD, MSCI, FACOG
Hear from Dr. Erica Marsh and Dr. Lee Shulman as they discuss the burden, prevalence, and treatment of uterine fibroids and endometriosis and the disproportionate impact these conditions have on vulnerable populations. Learn how to prioritize early diagnosis and treatment to improve outcomes for your patients; as well as evaluating barriers to proper diagnosis and treatment
Our experts offer strategies to guide discussions beyond surgical treatment approaches to include pharmacotherapeutic options such as GnRH agonists and new oral GnRH antagonists. Open communication with patients allows them to carefully consider symptom severity, risks, and fertility preferences to optimize treatment outcomes and patient satisfaction. Tune in to make sure that you’re really doing all you can for your patients.
Host: Andrea Singer, MD, FACP, CCD
Guest: Paul A. Anderson, MD
Guest: Susan V. Bukata, MD, FAOA, FAAOS
While there’s growing awareness among orthopedic surgeons that osteoporosis is the underlying cause of fractures, there is often a disconnect between this recognition and action in the form of treatment to prevent subsequent fractures. In this discussion, Drs. Andrea Singer, Paul Anderson, and Susan Bukata address the pathophysiology of osteoporosis and the need to identify patients at risk for additional fractures. Osteoporosis treatment (including pharmacotherapy) can play a critical role in preventing future fractures, but physicians must first recognize that fracture is a sentinel event and treat it as a call to action.
Host: Andrea Singer, MD, FACP, CCD
Guest: Paul A. Anderson, MD
Guest: Susan V. Bukata, MD, FAOA, FAAOS
While there’s growing awareness among orthopedic surgeons that osteoporosis is the underlying cause of fractures, there is often a disconnect between this recognition and action in the form of treatment to prevent subsequent fractures. In this discussion, Drs. Andrea Singer, Paul Anderson, and Susan Bukata address the pathophysiology of osteoporosis and the need to identify patients at risk for additional fractures. Osteoporosis treatment (including pharmacotherapy) can play a critical role in preventing future fractures, but physicians must first recognize that fracture is a sentinel event and treat it as a call to action.
Host: Paul Nyirjesy, MD
The global burden of acute vulvovaginal candidiasis (VVC) and the substantial morbidity and poor quality of life associated with recurrent disease (RVVC) requires improved solutions and quality of care for affected women. Join Dr. Paul Nyirjesy as he dissects the barriers to managing VVC and RVVC in your clinical practice and provides both diagnostic and therapeutic guidance inclusive of newly emerging and novel agents. These agents have unique qualities that may well represent a significant step forward in how you manage this challenging infection.
Host: Brooke M. Faught, DNP, WHNP-BC,NCMP, IF
Our patients express a number of misperceptions about combined hormonal non-LARC contraceptives such as the contraceptive patch, vaginal rings, and oral contraceptive pills. How well do you explain the advantages and disadvantages of these different options to your patients? How often have you prescribed what appeared to be a good contraceptive method for your patients only to have them be dissatisfied and become nonadherent?
Join Dr. Brooke Faught in this Women’s Health 2021 lecture as she tackles these issues and offers insights into how to discuss the full range of combined hormonal non-LARC contraceptive options with your patients using shared decision-making strategies. Remember, each patient’s needs, goals, and cultural background are important factors in a patient-centric approach to the choice of contraception.
Guest: Gregory Pokrywka MD, FACP, FNLA, FASPC, NCMP
Guest: Karol Watson, MD, PhD
Join us to discover optimal ways to identify women at risk or with atherosclerotic cardiovascular disease (ASCVD). In this Women’s Health 2021 lecture, our experts, Dr. Gregory Pokrywka and Dr. Karol Watson, dive deeper into evidence-based approaches to assess and manage ASCVD in women. They discuss topics from lifestyle modifications to recent clinical trial data on the use of omega-3 fatty acids for ASCVD event reduction.
Host: David L. Eisenberg, MD, MPH, FACOG
Many women prefer to use a nonhormonal contraceptive. They also want the freedom to self-administer on demand and want assurances that the contraceptive is safe, effective, and has received FDA approval. One such contraceptive is a self-administered, hormone-free gel that functions as a vaginal pH modulator. Join Dr. David Eisenberg as he describes the evolution of this vaginal pH modulator and the clinical trials leading to FDA approval. Even more significant is patient acceptance, which was remarkably high for this contraceptive. In fact, approximately 9 out of 10 women participating in the clinical trials indicated they would continue using the vaginal pH modulator and also recommend this novel method to their friends.
Host: Brooke M. Faught, DNP, WHNP-BC,NCMP, IF
Our patients express a number of misperceptions about combined hormonal non-LARC contraceptives such as the contraceptive patch, vaginal rings, and oral contraceptive pills. How well do you explain the advantages and disadvantages of these different options to your patients? How often have you prescribed what appeared to be a good contraceptive method for your patients only to have them be dissatisfied and become nonadherent?
Join Dr. Brooke Faught in this Women’s Health 2021 lecture as she tackles these issues and offers insights into how to discuss the full range of combined hormonal non-LARC contraceptive options with your patients using shared decision-making strategies. Remember, each patient’s needs, goals, and cultural background are important factors in a patient-centric approach to the choice of contraception.
Host: David L. Eisenberg, MD, MPH, FACOG
Many women prefer to use a nonhormonal contraceptive. They also want the freedom to self-administer on demand and want assurances that the contraceptive is safe, effective, and has received FDA approval. One such contraceptive is a self-administered, hormone-free gel that functions as a vaginal pH modulator. Join Dr. David Eisenberg as he describes the evolution of this vaginal pH modulator and the clinical trials leading to FDA approval. Even more significant is patient acceptance, which was remarkably high for this contraceptive. In fact, approximately 9 out of 10 women participating in the clinical trials indicated they would continue using the vaginal pH modulator and also recommend this novel method to their friends.
Host: Paul Nyirjesy, MD
The global burden of acute vulvovaginal candidiasis (VVC) and the substantial morbidity and poor quality of life associated with recurrent disease (RVVC) requires improved solutions and quality of care for affected women. Join Dr. Paul Nyirjesy as he dissects the barriers to managing VVC and RVVC in your clinical practice and provides both diagnostic and therapeutic guidance inclusive of newly emerging and novel agents. These agents have unique qualities that may well represent a significant step forward in how you manage this challenging infection.
Guest: Gregory Pokrywka MD, FACP, FNLA, FASPC, NCMP
Guest: Karol Watson, MD, PhD
Join us to discover optimal ways to identify women at risk or with atherosclerotic cardiovascular disease (ASCVD). In this Women’s Health 2021 lecture, our experts, Dr. Gregory Pokrywka and Dr. Karol Watson, dive deeper into evidence-based approaches to assess and manage ASCVD in women. They discuss topics from lifestyle modifications to recent clinical trial data on the use of omega-3 fatty acids for ASCVD event reduction.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Michelle Y. Owens, MD
OB-GYN clinicians can improve how they communicate with their patients about hemolytic disease of the fetus and newborn or HDFN. Strategies include encouraging patients to talk about their feelings when learning about this condition and communicating with them in terms that are not overly complex. In this program, Drs. Lee Shulman and Michelle Owens discuss how to break things down for the patient in front of you and explain how to use a read-back approach. This tactic ensures that your patient has absorbed what was discussed and also allows you to identify gaps in her understanding that can be addressed with further counseling.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Michelle Y. Owens, MD
OB-GYN clinicians can improve how they communicate with their patients about hemolytic disease of the fetus and newborn or HDFN. Strategies include encouraging patients to talk about their feelings when learning about this condition and communicating with them in terms that are not overly complex. In this program, Drs. Lee Shulman and Michelle Owens discuss how to break things down for the patient in front of you and explain how to use a read-back approach. This tactic ensures that your patient has absorbed what was discussed and also allows you to identify gaps in her understanding that can be addressed with further counseling.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Kenneth J. Moise, Jr., MD
Guest: Christopher Robinson, MD
Hemolytic disease of the fetus and newborn (HDFN) is a rare disease that occurs due to the incompatibility between fetal and maternal red cell antigens. HDFN can lead to both short- and long-term consequences, including potentially fatal outcomes. In order to better prevent these associated issues, the timely evaluation, recognition, and treatment of HDFN are critical.
Listen in as three leading experts, Drs. Lee Shulman, Kenneth Moise, and Christopher Robinson, join together to discuss new epidemiologic evidence, the underlying pathophysiology of HDFN, health equity, and evolving management strategies you can implement to improve your clinical practice.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Kenneth J. Moise, Jr., MD
Guest: Christopher Robinson, MD
Hemolytic disease of the fetus and newborn (HDFN) is a rare disease that occurs due to the incompatibility between fetal and maternal red cell antigens. HDFN can lead to both short- and long-term consequences, including potentially fatal outcomes. In order to better prevent these associated issues, the timely evaluation, recognition, and treatment of HDFN are critical.
Listen in as three leading experts, Drs. Lee Shulman, Kenneth Moise, and Christopher Robinson, join together to discuss new epidemiologic evidence, the underlying pathophysiology of HDFN, health equity, and evolving management strategies you can implement to improve your clinical practice.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Anna-Barbara Moscicki, MD
Updated cervical cancer screening guidelines were published by both the American Society for Colposcopy and Cervical Pathology (ASCCP) and the American Cancer Society (ACS). Dr. Lee Shulman leads a discussion with Dr. Anna-Barbara Moscicki on the recent guidelines, the range of cervical cancer screening tests, and the impact on risk stratification and patient management.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Anna-Barbara Moscicki, MD
Updated cervical cancer screening guidelines were published by both the American Society for Colposcopy and Cervical Pathology (ASCCP) and the American Cancer Society (ACS). Dr. Lee Shulman leads a discussion with Dr. Anna-Barbara Moscicki on the recent guidelines, the range of cervical cancer screening tests, and the impact on risk stratification and patient management.
Host: David L. Eisenberg, MD, MPH, FACOG
Guest: David J. Portman, MD
A new form of contraception based on vaginal pH modulation is available. In this activity, Dr. Eisenberg reviews the risks and benefits of the hormone-free, user-controlled gel, and Dr. Portman provides his perspective on clinical trial results within the context of the “creeping Pearl Index.”
Host: David L. Eisenberg, MD, MPH, FACOG
Guest: David J. Portman, MD
A new form of contraception based on vaginal pH modulation is available. In this activity, Dr. Eisenberg reviews the risks and benefits of the hormone-free, user-controlled gel, and Dr. Portman provides his perspective on clinical trial results within the context of the “creeping Pearl Index.”
Host: Linda Bradley, MD
In this activity, Dr. Linda Bradley reviews risk factors for uterine fibroids, the use of TVS,
Host: Linda Bradley, MD
In this activity, Dr. Linda Bradley reviews risk factors for uterine fibroids, the use of TVS,
Host: Nanette F. Santoro, MD
In this activity, Dr. Nanette F. Santoro explains risk factors for vasomotor symptoms, reviews current medical options for this bothersome problem, and describes the mechanism of action of a new class of nonhormonal agents: selective neurokinin-3 receptor antagonists.
Host: Nanette F. Santoro, MD
In this activity, Dr. Nanette F. Santoro explains risk factors for vasomotor symptoms, reviews current medical options for this bothersome problem, and describes the mechanism of action of a new class of nonhormonal agents: selective neurokinin-3 receptor antagonists.
Host: Floor J. Backes, MD
Guest: Robert L. Coleman, MD, FACOG, FACS
Does immunotherapy play a role in improving quality of life and survival for patients with ovarian cancer? Learn how experts are determining immunotherapy’s place in the treatment plan during the PARP era and what’s on the horizon.
Guest: David J. Portman, MD
Dr. David J. Portman demonstrates how clinicians can begin the conversation of dyspareunia with patients, as well as how to discuss the available treatment options for managing this condition in post-menopausal women.
Dr. Portman is Director Emeritus at Columbus Center for Women’s Health Research; and, Adjunct Instructor of Obstetrics and Gynecology at The Ohio State University, Columbus, OH.
Individual detection of 14 high risk human papilloma virus genotypes by the PapType test for the prediction of high grade cervical lesions. Cuzick J, Ho L, Terry G, Kleeman M, Giddings M, Austin J, Cadman L, Ashdown-Barr L, Costa MJ, Szarewski A. J Clin Virol. 2014 May;60(1):44-9. doi: 10.1016/j.jcv.2014.02.002. Epub 2014 Feb 14.
Abstract BACKGROUND:
HR HPV genotypes when assayed collectively, achieve high sensitivity but low specificity for the prediction of CIN2+. Knowledge of the specific genotypes in an infection may facilitate the use of HR HPV detection in routine clinical practice.
OBJECTIVES:
To compare the rate of HR HPV detection and the accuracy of CIN2+ prediction between PapType test (Genera Biosystems) and other commercially available HR HPV assays, and to examine the value of full HPV genotyping.
STUDY DESIGN:
PreservCyt samples from 1099 women referred for abnormal cervical cytology were used. CIN2+ was chosen as the primary end-point but CIN3+ was also evaluated. A hierarchy of HR HPV genotypes was created using PPV and this was used to create 3 groups of genotypes with potentially different …
Host: Thomas C. Wright, Jr., MD
A study of HPV typing for the management of HPV-positive ASC-US cervical cytologic results. Schiffman M, Vaughan LM, Raine-Bennett TR, Castle PE, Katki HA, Gage JC, Fetterman B, Befano B, Wentzensen N. Gynecol Oncol. 2015 Sep;138(3):573-8. doi: 10.1016/j.ygyno.2015.06.040. Epub 2015 Jul 4.
Abstract BACKGROUND:
In US cervical screening, immediate colposcopy is recommended for women with HPV-positive ASC-US(equivocal) cytology. We evaluated whether partial typing by Onclarity™ (BD) might identify HPV-positive women with low enough CIN3+ risk to permit 1-year follow-up instead.
METHODS:
The NCI-Kaiser Permanente Northern California Persistence and Progression cohort includes a subset of 13,890 women aged 21+ with HC2 (Qiagen)-positive ASC-US at enrollment; current median …